<DOC>
	<DOCNO>NCT00218465</DOCNO>
	<brief_summary>The purpose study evaluate efficacy glycine antagonist , GW468816 , compare placebo duration abstinence rate relapse recently quit female smoker randomize , double-blind , five-week clinical trial . According investigator , new medication , GW468816 , think send certain signal brain may effective help people stay abstinent recently quit smoking . GW468816 non-nicotine drug . The investigator study hypothesize subject receive GW468816 demonstrate significantly long time relapse smoke placebo group , measure primary outcome measure ( see ) .</brief_summary>
	<brief_title>Effectiveness GW468816 , NMDA Glycine Site Antagonist , Prevention Relapse Smoking</brief_title>
	<detailed_description>Smoking lead cause preventable mortality develop country . Pharmacotherapy , include bupropion nicotine replacement therapy ( NRT ) , universally recommend smoke cessation treatment ; however , even treatment , majority smoker either fail quit short term relapse first year . The high failure rate report smoking cessation , , present challenge explore innovative approach treat relapse smoking . The purpose study , , evaluate efficacy glycine antagonist , GW468816 , compare placebo duration abstinence rate relapse female outpatient smoker randomize , double-blind , five-week clinical trial . To , investigator conduct two-phase study , 300 adult , female outpatient smoker enrol . Phase I consist 8-week smoking cessation study nicotine replacement therapy ( NRT ) behavioral intervention openly administer tapered schedule . Participants able quit smoke 7 week preliminary study eligible enter Phase II . Phase II 5-week , double-blind , placebo-controlled , relapse prevention trial investigational medication , GW468816 . Participants Phase I smoke cessation study begin receive nicotine replacement therapy form patch brief support stop smoking . Participants require schedule office visit every 1-2 week throughout Phase I . Subjects abstinent end Phase I eligible continue Phase II , randomly assign chance receive investigational medication , GW468816 , 200 mg placebo ( pill look exactly like study drug contains active drug ) . Participants require schedule weekly office visit throughout Phase II . Subjects complete 15-week trial ( Phases I II ) enter 6-Month Follow-Up evaluate rate long term abstinence nicotine . They office visit Weeks 20 , 24 , 28 , 32 , 36 , 40 discontinuation study medication . Participants enter study offer opportunity participate ancillary neuroimaging study mechanism surrogate marker relapse include BOLD fMRI MR spectroscopy , carry McLean Brain Imaging Center .</detailed_description>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Tobacco Use Disorder</mesh_term>
	<mesh_term>Nicotine</mesh_term>
	<mesh_term>Glycine</mesh_term>
	<criteria>1 . Written inform consent 2 . WOMEN age 1865 year , inclusive 3 . Selfreport smoke 10 cigarette per day past 6 month expire air CO &gt; 10 ppm time enrollment 4 . DSMIV criterion current Nicotine Dependence satisfy 5 . Subjects must willing take study medication motivate quit smoking ( willing set quit date within 2 week entry protocol ) 6 . Women childbearing potential must negative urine pregnancy test ( quantitative HCG ) baseline week 8 , prior receive first dose study medication female must agree use approved form contraception day first dose study medication 90 day last dose study medication . Approved forms contraception include follow : Complete abstinence intercourse 2 week prior administration study drug , treatment phase 90 day discontinuation study medication . Sterilization male partner Implant levonorgestrel Injectable progesterone Intrauterine device ( IUD ) &lt; 1 percent rate failure per year Any method publish rate failure &lt; 1 percent per year Due induction cytochrome p450 3A4 , oral contraceptive may continue study rely upon sole mean contraception , second method contraception barrier method require reimburse study . 1 . Pregnant able become pregnant willing use approve contraception 2 . Severe unstable medical illness include cardiovascular , hepatic , renal , respiratory , metabolic , neurological , hematological disease history , physical examination clinical laboratory test result hospitalization treatment illness likely within next two month 3 . Lifethreatening arrhythmia , cerebrovascular cardiovascular event within six month enrollment 4 . Elevation 1.5 time upper limit normal value ( ULN ) follow laboratory result : Total , conjugate , unconjugated bilirubin ; alkaline phosphatase , alanine transferase ( ALT ) , aspartate aminotransferase ( AST ) , creatine phosphokinase ( CPK ) , lactate dehydrogenase ( LDH ) . 5 . Use tobaccocontaining product cigarette ( e.g. , cigar , pipe ) 6 . Abuse dependence substance nicotine caffeine past 6 month . Abuse alcohol define average weekly intake great 21 unit average daily intake great three unit ( male ) define average weekly intake great 14 unit average daily intake great two unit ( female ) . One unit equivalent halfpint ( 220mL ) beer one ( 25mL ) measure spirit one glass ( 125mL ) wine . 7 . Diagnosis major depressive disorder past 6 month 8 . Lifetime DSMIV diagnosis organic mental disorder , schizophrenia , schizoaffective disorder , bipolar disorder , delusional disorder psychotic disorder elsewhere classify 9 . History nonresponse past month adequate trial nicotine placement therapy , define nicotine replacement &gt; 21 mg per day patch ( equivalent dose gum , inhaler , nasal spray , lozenge ) least 4 week . 10 . History multiple adverse drug reaction 11 . Use investigational drug device within 4 week enrollment 12 . Concurrently enrol study involve exposure drug device . 13 . Urine positive drug abuse screen visit . 14 . Use statins period investigation .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Drugs , Investigational</keyword>
	<keyword>Therapies Relapse Nicotine</keyword>
	<keyword>Relapse Prevention</keyword>
	<keyword>Nicotine Cessation Therapies</keyword>
	<keyword>Smoking Cessation</keyword>
	<keyword>Nicotine Dependence</keyword>
</DOC>